Creo Medical Regulatory News (CREO)

Creo Medical Group plc

("Creo" the "Company" or the "Group")

Attendance at Digestive Disease Week

Creo Medical Group plc (AIM: CREO), the medical device company focused on the emerging field of surgical endoscopy, updates on a hugely successful Digestive Disease Week ("DDW"), the world's premier meeting for physicians, researchers and industry in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery, in Chicago, USA.

This year's DDW, which was attended by over 12,500 international delegates, took place between 6-9 May 2023. Creo used the event to showcase its products and technologies with the Company's Speedboat Inject device a headline attraction.

Highlights from the event include:

- A 288% year on year increase in sales leads directly from the event (compared with 2022 DDW)

- Booth visitors from 28 different countries

- A dramatic increase in showcased poster presentations and lectures focusing on the role of Speedboat Inject in endoscopic procedures, with one shortlisted and presented at the primary presentation hall for the final day's round up ASGE plenary session

- Premier clinicians from across the globe attending Creo Medical's 'Advancing Energy in Third Space Endoscopy: Exploring New Possibilities' symposium, held in conjunction with DDW, including world famous endoscopy experts Prof Hinori Yamamoto and Prof Naohisa Yahagi from Japan

- Exciting developments in progressing and finalising distribution agreements for new territories

- Providing many leading physicians with a first glimpse of proto-types and pre-release devices behind closed doors

Creo Medical CEO Craig Gulliford said:

"DDW is an annual event bringing together the world's leading minds in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery, with this year's the most significant in our history.

"From presentations and lectures to interest and accolades, we are now seeing Upper GI gastroenterologists, Lower GI Gastroenterologists, Foregut Surgeons, Colorectal surgeons and a whole host besides demonstrating to their peers what our advanced energy devices are delivering for healthcare providers and their patients. It's a real step change in our presence over previous years."  

David Woods, Chief Commercial Officer of Creo, added:  

"It's fantastic to see the significant increase in sales leads, orders and broader interest from every corner of the globe during and following what has been a hugely productive DDW for Creo.

"Whilst DDW is one of the largest events in the US GI calendar, it is just one of a number of key exhibitions Creo is attending this Spring including a busy ESGE (European Society of Gastrointestinal Endoscopy Days 2023), which occurred in late April, and several upcoming showcase events in the EMEA and APAC over the coming weeks. At each, live Speedboat Inject case features and hands-on experiences are shown, supported by renowned clinicians in the field, underlining how the momentum and adoption of Creo's medtech is growing apace."

Enquiries:

About Creo Medical 

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes. Kamaptive is a seamless, intuitive integration of multi-modal energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation and ablation of tissue. Kamaptive technology provides clinicians with increased flexibility, precision and controlled surgical solutions. CROMA currently delivers bipolar radiofrequency ("RF") energy for precise localised cutting and focused high frequency microwave ("MW") energy for controlled coagulation and ablation via a single accessory port. This technology, combined with the Group's range of patented electrosurgical devices, is designed to provide clinicians with flexible, accurate and controlled clinical solutions. The Directors believe the Company's technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option for procedures.

For more information, please refer to the website www.creomedical.com